throbber
An inhibitor of mTOR reduces neoplasia and
`normalizes p70yS6 kinase activity in
`Pten1/2 mice
`
`Katrina Podsypanina*, Richard T. Lee*, Chris Politis*, Ian Hennessy*, Allison Crane*, Janusz Puc*, Mehran Neshat†,
`Hong Wang‡, Lin Yang*, Jay Gibbons§, Phil Frost§, Valley Dreisbach¶, John Blenis¶, Zbigniew Gaciongi,
`Peter Fisher*, Charles Sawyers†, Lora Hedrick-Ellenson‡, and Ramon Parsons*,**
`
`*Institute of Cancer Genetics, Departments of Pathology and Medicine, College of Physicians and Surgeons, Columbia University, 1150 St. Nicholas Avenue,
`Russ Berrie Pavilion, New York, NY 10032; †Department of Medicine, Molecular Biology Institute, University of California, Los Angeles, CA 90095-1678;
`‡Department of Pathology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021; §Wyeth-Ayerst Research, 401
`Middletown Road, Pearl River, NY 10965; ¶Department of Cell Biology, Harvard Medical School, Boston, MA 02115; and iDepartment of
`Internal Diseases and Hypertension, Medical University of Warsaw, 1a Banacha Street, 02-097 Warsaw, Poland
`
`Edited by Bert Vogelstein, Johns Hopkins Oncology Center, Baltimore, MD, and approved June 14, 2001 (received for review February 6, 2001)
`
`PTEN phosphatase acts as a tumor suppressor by negatively reg-
`ulating the phosphoinositide 3-kinase (PI3K) signaling pathway. It
`is unclear which downstream components of this pathway are
`necessary for oncogenic transformation. In this report we show
`that transformed cells of PTEN1/2 mice have elevated levels of
`phosphorylated Akt and activated p70yS6 kinase associated with
`an increase in proliferation. Pharmacological inactivation of mTORy
`RAFTyFRAP reduced neoplastic proliferation, tumor size, and
`p70yS6 kinase activity, but did not affect the status of Akt. These
`data suggest that p70yS6K and possibly other targets of mTOR
`contribute significantly to tumor development and that inhibition
`of these proteins may be therapeutic for cancer patients with
`deranged PI3K signaling.
`
`The PTEN tumor suppressor is mutated in a wide variety of
`
`human sporadic and inherited cancers (1). PTEN acts as a
`negative regulator of the phosphoinositide 3-kinase (PI3K)
`signaling pathway by dephosphorylating the second messengers
`phosphatidylinositol-3,4,5-trisphosphate [PtdIns(3,4,5)P3] and
`phosphatidylinositol-3,4-bisphosphate [PtdIns(3,4)P2] at the D3
`position of the inositol ring, thereby opposing PI3K function (2).
`Consistent with the role of PTEN as a PtdIns(3,4,5)P3 phospha-
`tase, Pten-deficient cells have elevated levels of intracellular
`PtdIns(3,4,5)P3 (3, 4).
`In flies, expression of PTEN can rescue lethality caused by
`overexpression of d-PI3K (Dp110) or the fly insulin receptor
`(Inr) (5, 6). The loss-of-function phenotypes of dPTEN, in-
`creased cell size and proliferation, are suppressed by inactivating
`mutations in dAKT1 and the translational initiation factor eif4A,
`suggesting that dPTEN acts through the AKT-signaling pathway
`to regulate translation (7). Loss-of-function mutations in an-
`other translational regulator, Drosophila p70yS6 kinase (dS6K)
`(8), as well as its upstream regulators dPI3K, Inr, and chico (fly
`insulin receptor substrate 1–4) decrease cell size in Drosophila
`(9). For p70yS6 kinase (S6K) the ability to control cell size is
`conserved in mammals (10, 11). In addition, S6K2/2 mouse
`embryonic stem cells have a defect in proliferation with a greater
`proportion of cells in G0yG1 (10). The increased size and
`proliferation of dPTEN-deficient cells is consistent with the
`antagonistic role of PTEN in the PI3K-signaling pathway and
`suggests that PTEN may play a role in regulating S6K.
`Mitogen-induced activation of S6K is mediated through the
`PI3K-dependent phosphorylation of several residues (12, 13).
`This activation is in part performed by 3-phosphoinositide-
`dependent kinase 1 (14, 15). In addition, membrane-tethered
`AKT is able to activate S6K, whereas untethered, activated
`mutants of AKT do not have this effect (16). Activation of S6K
`can be blocked by the pharmacological agent rapamycin (17, 18).
`Rapamycin has potent immunosuppressant and tumor inhibitory
`
`activities (19). To exert its effect, rapamycin binds an immu-
`nophilin, FK-506-binding protein 12, and this complex inhibits
`the cellular target of rapamycin, mTORyRAFTyFRAP (20–22).
`mTOR is a member of the ataxia-telangiectasia-mutated (ATM)
`family of kinases that seems to function in a checkpoint for
`nutritional status in G1 and in response to the PI3KyAKT
`pathway (23, 24). AKT can directly phosphorylate mTOR (25,
`26), although the impact of this phosphorylation on the activity
`of mTOR has not been firmly established. Several studies have
`demonstrated control of S6K activity by mTOR by direct (27, 28)
`and indirect (29–31) mechanisms. Recent studies of the fly
`homolog of mTOR, dTOR, have demonstrated that mutants of
`dTOR have reduced cell size and proliferation and fail to
`develop to maturity (32, 33). Overexpression of dS6K rescued
`dTOR mutants from embryonic lethality (32). Moreover, the
`large cell size and hyperproliferative phenotypes of dPTEN were
`completely masked by mutation of dTOR. These data suggest
`that dS6K is a critical downstream target of dTOR and dPTEN.
`S6K is amplified and overexpressed in breast cancer, which
`suggests a potential oncogenic function (34, 35). Constitutive
`activation of S6K in PTEN-deficient tumor cells has been
`reported previously and can be corrected by reintroduction of
`PTEN (36). To investigate the potential contribution of the
`mTORyS6K pathway to the transformation induced by Pten loss,
`we examined the effect of inhibiting mTOR with the rapamycin
`ester CCI-779 in the Pten1/2 mouse tumor model system.
`
`Materials and Methods
`Mice and Treatment. Pten1/2 mice were generated as described
`(37). The rapamycin analog CCI-779 was provided by Wyeth
`Ayerst Laboratories (Marietta, PA). The drug was first diluted
`to 50 mgyml in 100% ethanol and then quickly mixed with 5%
`Tween-80 (GIBCOyBRL)y5% polyethylene glycol-400 (Sigma)
`to a 2 mgyml drugy4% ethanol final concentration. The drug
`solution, or the vehicle alone, was delivered to mice through the
`tail vein at a dose of 20 mgykg (10 mlyg of body weight).
`Histology. Mice were given i.p. injections of 125 mgykg of BrdUrd
`(Sigma) 1 h before euthanasia. Organs for histological analysis
`
`This paper was submitted directly (Track II) to the PNAS office.
`
`Abbreviations: PI3K, phosphoinositide 3-kinase; CAH, complex atypical hyperplasia;
`PtdIns(3,4,5)P3, phosphatidylinositol-3,4,5-trisphosphate; TUNEL, terminal deoxynucleoti-
`dyltransferase-mediated dUTP nick end labeling.
`
`See commentary on page 10031.
`
`**To whom reprint requests should be addressed. E-mail: rep15@columbia.edu.
`
`The publication costs of this article were defrayed in part by page charge payment. This
`article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C.
`§1734 solely to indicate this fact.
`
`10320 –10325 u PNAS u August 28, 2001 u vol. 98 u no. 18
`
`www.pnas.orgycgiydoiy10.1073ypnas.171060098
`
`Roxane Labs., Inc.
`Exhibit 1027
`Page 001
`
`

`
`MEDICALSCIENCES
`
`were kept in 10% formalin overnight, then changed to 70%
`ethanol. Paraffin embedding was performed no later than a week
`after organ collection. For the long-term CCI-779 experiment,
`paraffin tissue blocks from individual mice were coded from 1 to
`20 and hematoxylinyeosin stains of those were analyzed in
`blinded fashion by at least three investigators (K.P., R.P., P.F.,
`and L.H.-E.). Catecholamines were measured from blood col-
`lected at the time of death with an HPLC kit from Bio-Rad
`according to the manufacturer’s instructions.
`
`immunohistochemistry stains were
`Immunohistochemistry. All
`performed on 4-mm-thick tissue slices as described (38). The
`following antibodies and dilutions were used: mouse monoclonal
`anti-BrdUrd (Becton Dickinson) 1:200, rabbit polyclonal anti-
`PTEN (Neomarkers Ab-2) 1:500, rabbit polyclonal anti-
`phospho-AKT (Ser-473; NEB, Beverly, MA) 1:50, and mouse
`monoclonal anti-p27 (Transduction Laboratories, Lexington,
`KY) 1:500. Apoptosis was measured with the terminal
`deoxynucleotidyltransferase-mediated dUTP nick end labeling
`(TUNEL) assay. Positive controls included irradiated organs
`and DNase-treated sections. The apoptotic index was calculated
`similar to the BrdUrd incorporation index (see below). TUNEL
`staining was performed on paraffin-embedded sections that
`were deparaffinized in xylenes and transferred to 95% methanol
`and then water. Slides then were treated with 20 mgyml pro-
`teinase K for 20 min, washed, and endogenous peroxidases were
`blocked in 3% H2O2 in methanol, dipped in terminal de-
`oxynucleotidyltransferase (TdT) buffer, and incubated for 60
`min at 37°C with the TdTyBio-16-dUTP mix. After a wash, slides
`were incubated with Avidin-horseradish peroxidase (Dako)
`1:400 for 20 min. The horseradish peroxidase substrate 3-amino-
`9-ethylcarbazole was incubated with the slides in a glass con-
`tained in the acetate buffer (10.5 mM acetic acidy80 mM Na
`acetate solution, pH 5.5) until full color development and
`counterstained with Mayer’s hematoxylin.
`
`Measurement of Proliferation, Apoptosis, Lesion Size. Anti-BrdUrd
`and TUNEL-stained uterine cross-sections (3–5 per mouse) and
`adrenal medullas were acquired at 340 magnification by a
`Diagnostic Instruments (Sterling Heights, MI) digital SPOT
`(Diagnostic Instruments, Sterling Heights, MI) camera in Adobe
`PHOTOSHOP. Vertical and horizontal diameters of the uteri,
`complex atypical hyperplasia (CAH) lesions, and medullas were
`measured by using the loop tool. All BrdUrd- and TUNEL-
`positive cells were counted in the secretory epithelium of the
`uterus and in the medulla. Resulting numbers were entered in a
`Microsoft EXCEL spreadsheet. Areas were calculated by averag-
`ing horizontal and vertical diameters to obtain the radius. The
`BrdUrd and TUNEL indexes for adrenals in all experiments and
`untreated and short-term-treated uterine samples were calcu-
`lated by dividing the absolute number of positive cells by the
`uterine or adrenal section area. In transition zones, up to 100
`nuclei were counted in transformed and nontransformed re-
`gions, and the BrdUrd index was calculated per total number of
`nuclei. For the long-term treatment group, all secretory epithe-
`lial cells were counted in one section per mouse, and the BrdUrd
`and TUNEL index was calculated per total number of cells.
`Lesions in stained sections were acquired at 325 magnification
`and measured with use of NIH IMAGE 1.62. P values were calcu-
`lated with Student’s t test. Error bars represent standard devi-
`ation. P values were obtained by comparing two given groups by
`Student’s two-tailed t test.
`
`Western Blotting. Frozen uteri and adrenals were ground in liquid
`nitrogen by mortar and pestle and tissue powder was transferred
`into 13 loading buffer and boiled for 5 min. Samples were spun
`and soluble protein concentrations were determined before
`loading on a gel. Antibodies to AKT and phospho-389-S6K were
`
`obtained from NEB and anti-tubulin was purchased from Babco
`(Richmond, CA). The C-2 antibody for S6K was used.
`
`Pten Loss of Heterozygosity. To study loss of heterozygosity of
`Pten in the CAH of the endometrium, the wild-type and
`mutant alleles were amplified from DNA prepared from
`microdissected, formalin-fixed, paraffin-embedded uterine le-
`sions. Both the mutant and wild-type alleles were amplified
`simultaneously by using a common 59 primer within intron 4
`and two 39 primers, one within exon 5 of Pten and one within
`the Pgk gene: GGGATTATCTTTTTGCAACAGT (Pten 59),
`GGCCTCTTGTGCCTTTA (Pten 39), and TTCCTGAC-
`TAGGGGAGGAGT (Pgk 39). Tail DNAs of a healthy PTEN
`heterozygous mouse and a wild-type mouse were used as
`controls. PCR was performed in 50-ml reactions containing 10
`mM TriszHCl (pH 9.2), 1.5 mM MgCl2, 75 mM KCl, 0.4 mM of
`each 39 primer, 0.8 mM 59 primer, 160 mM each dNTP, and 2.5
`units of Taq polymerase(GIBCO). Forty cycles of PCR were
`performed; each cycle consisted of 1 min at 95°C, 1 min at
`57°C, and 1 min at 72°C followed by a single 5-min extension
`at 72°C. To study the loss of heterozygosity of Pten in the
`adrenals, Southern blotting was performed on DNA extracted
`from normal adrenals, pheochromocytomas, and tail DNA as
`a control. 39 probe flanking the targeted region was used on
`the PstI-digested DNA.
`
`S6K Assay. The S6K kinase assay was performed essentially as
`described previously (10, 39). In short, frozen uteri of 35- to
`50-week-old animals were homogenized in 10 mM KPO4, 10 mM
`MgCl2, 1 mM EDTA, and 0.1% Nonidet P-40 in the presence of
`protease and phosphatase inhibitors. Protein concentration was
`measured from the soluble fraction, and samples were normal-
`ized to equal protein concentration in each experiment. S6K was
`immunoprecipitated from tissue lysates with protein AyG aga-
`rose (C-18, Santa Cruz Biotechnology) at 4°C overnight. Sam-
`ples were washed twice in the lysis buffer followed by a wash in
`kinase buffer (20 mM Tris, pH 7.5y10 mM MgCl2y0.1 mg/ml
`BSAy0.4 mM DTT). The kinase reaction was performed at 30°C
`for15 min in the presence of 100 mM ATP, 200 mCiyml
`[g-32P]ATP, and 125 mM S6 peptide substrate (Upstate Bio-
`technology, Lake Placid, NY). Stopped reactions were loaded
`onto phosphocellulose columns (Pierce) and unbound label was
`washed with 75 mM phosphoric acid. Bound, labeled probe was
`measured in a liquid scintillation counter.
`
`Results
`To use the Pten1/2 mice for preclinical trials of candidate drugs,
`the penetrance and variability of tumor phenotypes was docu-
`mented. Multifocal CAH developed in the uterine secretory
`epithelium of almost every (29y30) Pten1/2 female mouse by 26
`weeks of age. Two types of transformed lesions were present:
`cribriform glands and transformed cysts. Cribriform glands were
`defined as continuous foci of crowded glands. Transformed cysts
`were defined as cavities fully or partially lined with transformed
`epithelium. Some cavities appeared empty and some were filled
`with necrotic masses. In some sections a stretch of normal
`epithelium was observed in the cyst wall, with a clear transition
`zone between normal and transformed epithelium. Some of the
`older wild-type mice had cysts in the endometrium, but the
`epithelial lining was never transformed. We also observed that
`nearly all of the Pten1/2 mice developed neoplasia of the
`chromaffin cells of the adrenal medulla by 6 months (48y49; Fig.
`1 A and B). This neoplasia was bilateral and multifocal. In mice
`more than 1 year of age the tumors were frequently diagnosed
`as pheochromocytomas. Elevated serum levels of both norepi-
`nephrine (P 5 0.069) and epinephrine (P 5 0.039) suggested that
`the tumor cells retained some of the functional characteristics of
`the chromaffin cell (Fig. 1 C and D).
`
`Podsypanina et al.
`
`PNAS u August 28, 2001 u vol. 98 u no. 18 u 10321
`
`Roxane Labs., Inc.
`Exhibit 1027
`Page 002
`
`

`
`Pten1/2 mice develop pheochromocytomas of the adrenal medulla.
`Fig. 1.
`Morphology of the wild-type adrenal (A) and the Pten1/2 adrenal containing
`a pheochromocytoma (B). (Magnification, 340.) The normal medulla can be
`seen in the center of the wild-type adrenal cortex. Paraffin sections were
`stained with hematoxylinyeosin. PTEN1/2 animals (mutant) have elevated
`levels of serum norepinephrine (C) and epinephrine (D) relative to wild type.
`
`Proliferation Is Increased in the Lesions. Loss of Pten has been
`linked to both increased proliferation and to defects in apoptosis.
`To investigate whether either of these mechanisms contributed
`to uterine neoplasia, we first studied the frequency of BrdUrd
`incorporation in wild-type and mutant uteri of 35- to 38-week-
`old animals. Overall, Pten1/2 uterine CAH had a 2-fold increase
`in BrdUrd-positive cells when compared with wild-type secre-
`tory epithelium (1y2, n 5 4; wild type, n 5 3; Fig. 2A). Analysis
`of seven cystic lesions composed of both transformed and
`untransformed epithelium revealed a 3-fold increase in BrdUrd-
`positive cells in the transformed epithelium (Fig. 2B; P 5 0.007).
`At the same time we measured the level of BrdUrd incorporation
`in the adrenal medulla. We found that there was a substantial
`increase in the proliferation of medullary cells of Pten1/2 mice
`that occurred in regions of neoplasia (Fig. 2 C–E; P , 0.001).
`
`Increased proliferation in the neoplastic regions of Pten1/2 uteri and
`Fig. 2.
`adrenals. Mice were injected with 125 mgykg of BrdUrd for 1 h before death
`and sections were stained with an antibody recognizing BrdUrd. (A) Prolifer-
`ation index in Pten1/1 (h) and Pten1/2 (n) uteri was calculated by comparing
`the proliferation index of the secretory epithelium in wild type with that of
`the CAH. (B) Proliferation index in normal (h) and transformed (n) regions of
`cysts of Pten1/2 uteri. BrdUrd-positive cells were counted per total number of
`nuclei. (C) Proliferation index of wild-type (h) and 1y2 (n) adrenal medulla.
`Error bars indicate SD. Examples BrdUrd staining of the wild-type (D) and
`Pten1/2 (E) medulla. Increased BrdUrd incorporation can be seen in E relative
`to D.
`
`Fig. 3. Neoplastic lesions in Pten1/2 uteri have lower levels of Pten, and
`higher active Akt. (A) Loss of heterozygosity in hyperplastic lesions of the
`endometrium. Products from wild-type and mutant Pten alleles are amplified
`in a duplex reaction. Controls consist of products generated from tail DNA
`isolated from Pten heterozygous (lane 1) and wild-type (lane 2) mice. Lanes 3,
`4, and 5 are amplified products from microdissected, hyperplastic endometrial
`lesions from three Pten heterozygous mice at 32 weeks of age. Loss of the
`wild-type Pten allele is present in one lesion (lane 3), and both alleles are
`retained in the other two lesions (lanes 4 and 5). (B) Loss of heterozygosity in
`Pten1/2 adrenals. Adrenal DNA was prepared from six Pten1/2 mice. After
`probing the wild-type (wt) and mutant alleles (mut) (arrowheads), we ob-
`served that five of the six Pten1/2 adrenals had undergone loss of heterozy-
`gosity. Control (1y2) and wild-type DNA (1y1) were prepared from tails.
`(C–E) Transition zone in Pten1/2-transformed uterine cysts. Slides were stained
`with hematoxylinyeosin (C), rabbit polyclonal anti-PTEN (D), and rabbit poly-
`clonal anti-phospho-AKT (Ser-473) (E). (Magnification, 3600.) (F and G) Al-
`tered PTEN and phospho-AKT expression are detected in the adrenal medulla.
`Reduced PTEN staining correlates with transformation and phospho-AKT
`staining. (F) A small representative focus of reduced PTEN expression in a
`Pten1/2 adrenal medulla. Notice that most PTEN staining within the medullary
`cells occurs in the nucleus. (G) A small focus of increased phospho-AKT staining
`correlates with reduced PTEN expression. (Magnification, 3600.) Cortex (C)
`stains nonspecifically for PTEN and phospho-AKT.
`
`With use of terminal deoxynucleotidyltransferase labeling of
`DNA nicks with the TUNEL assay on the same tissues, no
`difference in the apoptotic frequency was observed between
`wild-type and heterozygous tissues (data not shown).
`
`Loss of the Wild-Type Allele Occurs in the Lesions. Uteri then were
`examined for loss of wild-type Pten. Protein expression analysis
`of the total lysates of mutant uteri demonstrated reduced PTEN
`expression relative to wild type (data not shown). PCR analysis
`of the individual lesions in seven Pten1/2 mice detected loss of
`the wild-type Pten allele in 30% (9y30) lesions studied (Fig. 3A).
`An example of loss of heterozygosity in a lesion is shown in lane
`3; lesions with no discernible loss of heterozygosity are shown in
`lanes 4 and 5 (Fig. 3A). The frequency of loss may be an
`underestimate because of normal tissue contamination during
`microdissection. In the adrenal lesions, loss of the wild-type
`
`10322 u www.pnas.orgycgiydoiy10.1073ypnas.171060098
`
`Podsypanina et al.
`
`Roxane Labs., Inc.
`Exhibit 1027
`Page 003
`
`

`
`MEDICALSCIENCES
`
`S6K activity but not AKT phosphorylation can be inhibited with
`Fig. 4.
`CCI-779. (A) S6K activity in Pten1/2 (F), Pten1/2 treated with CCI-779 for 3 days
`(E), and Pten1/1 (h) uterine lysates. Protein concentration was measured from
`the soluble fraction, and samples were normalized for equal protein concen-
`tration before the immunoprecipitation and measurement of S6K activity. (B)
`Short-term CCI-779 treatment reduces the BrdUrd incorporation index. Br-
`dUrd incorporation index in mock (n)- and drug (h)-treated Pten1/2 uterine
`epithelium treated for 3 days with vehicle or CCI-779. (C) Phosphorylated S6K
`levels in 293 cell line and mouse uterine lysates. (Lanes 1 and 2) 293 cells pulsed
`with epidermal growth factor or starved. Note reduced mobility of S6K in lane
`1. Pten1/1 (lanes 3 and 4) and Pten1/2 (lanes 5– 8) uterine lysates analyzed on
`an 8% polyacrylamide gel. Frozen uteri were ground and transferred into
`loading SDS buffer, and protein concentrations were normalized by anti-
`MAPK signal. A slower migrating band was seen in lysates of mice that were
`not treated with CCI-779 (lanes 7 and 8). This band was not present in Pten1/2
`lysates of mice treated with CCI-779 for 3 days (lanes 5 and 6) or in treated or
`untreated wild-type lysates (lanes 3 and 4). (D) Uterine (Upper) and adrenal
`(Lower) lysates from wild-type (1y1) and mutant animals (1y2) were re-
`solved on a 4 –20% gradient gel, blotted, and probed with anti-phospho-473
`and total AKT antibodies. Each sample was collected from a Pten1/2 mouse
`injected with either diluent or CCI-779 (Drug) for 3 days.
`
`(weeks 1, 2, 4, 6, and 8: 5 days on, 2 days off; weeks 3, 5, 7: 7 days
`off; week 9: 4 days on, 3 days off; week 10: 2 days on). Tissues
`were collected on the day after the last injection. Long-term
`treatment with CCI-779 produced detectable improvement in
`the health of the animals. Animals receiving drug injections
`appeared more active, and by the end of the study all were alive,
`whereas three animals died in the untreated and mock-treated
`groups. The cause of death was not determined, but was typically
`caused by uterine or gastrointestinal tumors.
`We chose to focus on the drug’s effect on the two tumor
`phenotypes with the highest penetrance by 25 weeks of age,
`uterine and adrenal medullary neoplasia. Morphological analysis
`showed that drug-treated Pten heterozygotes had a marked
`reduction in uterine and adrenal lesion size when compared with
`the mock-treated or untreated group (Fig. 5 A and B; P 5 0.09,
`P 5 0.039). However, the effect appeared to be cytostatic
`because lesion size of the treated group and untreated 26-week-
`old mice was similar. Drug-treated mice also had a substantial
`reduction in the frequency of BrdUrd incorporation in both
`types of neoplasia relative to mock-treated controls (Fig. 5 C and
`D; P 5 0.028, P , 0.001). Immunohistochemical analysis of
`uterine sections still detected reduced Pten and activated Akt
`levels in drug-treated lesions (n 5 35),
`indicating that the
`intervention occurred downstream of these molecules (Fig. 5 E
`and F). Although both PTEN and rapamycin have been linked
`to the regulation of p27, no alteration of p27 was detected by
`
`allele was observed in five of six heterozygous adrenals by
`Southern blotting (Fig. 3B).
`
`Neoplasia Is Characterized by Reduced PTEN Expression and Increased
`Phosphorylation of AKT. Immunohistochemical analysis of uterine
`sections demonstrated that untransformed epithelial cells
`stained intensely for PTEN in the cytoplasm, whereas signifi-
`cantly decreased levels of Pten staining occurred in regions of
`transformation (n 5 60; Fig. 3 C and D). Pten-deficient cells
`typically have activated AKT. Analysis of phosphorylated Akt in
`the serial sections of the uteri of Pten1/2 mice detected phospho-
`Akt (Ser-473) in all of the areas of transformation (n 5 60) in
`a membrane-specific pattern (Fig. 3E). The signal also corre-
`sponded precisely to the areas of Pten down-regulation. Staining
`for total AKT revealed that nearly all of the AKT shifted from
`the cytoplasm and nucleus in normal epithelium to the mem-
`brane in CAH (data not shown). We did not detect phospho-Akt
`in any of the uterine sections of 35- to 38-week-old wild-type
`mice (data not shown). In the adrenal medulla, staining for
`PTEN occurred in both the nucleus and cytoplasm of medullary
`chromaffin cells (Fig. 3F). In Pten1/2 mice, multifocal regions of
`reduced PTEN expression were found. An example of a focus of
`reduced staining is shown in Fig. 3F. In addition, increased
`staining for phospho-AKT could be detected in areas of reduced
`PTEN staining (Fig. 3G).
`
`Altered Activity of S6K in the Neoplastic Uterus. Because CAH was
`consistently found in older Pten1/2 mice, we decided to deter-
`mine whether S6K kinase activity was elevated in their uteri. We
`also tested whether a mTOR inhibitor could affect S6K activity
`in established endogenous tumors. We chose to use the rapa-
`mycin ester, CCI-779, which was developed for i.v. administra-
`tion in cancer patients (19, ††). For 3 days, 34- to 44-week-old
`Pten1/2 females were injected once daily with 20 mgykg CCI-779
`or the vehicle only. The choice of dose was based on prior studies
`of mouse response to CCI-779 (J.G., unpublished observations).
`Tissues were collected on the last day of injection from treated
`(n 5 3) and untreated (n 5 4) Pten1/2 and untreated wild-type
`(n 5 4) mice. S6K activity was elevated in the uteri of heterozy-
`gous mice relative to wild type (Fig. 4A). CCI-779 seemed to
`inhibit kinase activity to wild-type levels. Uterine lysates also
`were analyzed for the mobility of S6K, because its slower
`migrating form is associated with increased phosphorylation and
`kinase activity. Lysates from starved and epidermal growth
`factor-pulsed 293 cells were loaded as controls for the detection
`of the fast- and slow-moving species. The slow-moving species of
`S6K was observed only in the epidermal growth factor-treated
`293 lysate and the lysates from two untreated Pten heterozygous
`uteri (Fig. 4C). CCI-779 treatment led to the presence of only the
`hypophosphorylated, inactive, and faster migrating form. Uteri
`of Pten heterozygous females that received CCI-779 injections
`for 3 days had a modest 40% reduction in epithelial proliferation
`(Fig. 4B). Although CCI-779 had a marked effect on S6K
`activity, the level of phospho-Akt (Ser-473) was not affected in
`either uterine or adrenal tissues (Fig. 4D). No difference in
`apoptosis levels was detected among the different groups as
`assessed by terminal deoxynucleotidyltransferase labeling of
`DNA nicks (data not shown).
`
`Trial of CCI-779 in Pten1y2 Mice. To determine whether CCI-779
`could be used to treat the mouse tumors, a longer course of
`CCI-779 was given. A second group of Pten1/2 females (24–28
`weeks old) were injected daily with 20 mgykg CCI-779 (n 5 7)
`or vehicle (n 5 7), or were left untreated (n 5 6) for 10 weeks
`
`††Gibbons, J. J., Discafani, C., Petersen, R., Hernandez, R., Skotnicki, J. & Frost, P. (1999) Proc.
`Am. Assoc. Cancer Res. 40, 301 (abstr.).
`
`Podsypanina et al.
`
`PNAS u August 28, 2001 u vol. 98 u no. 18 u 10323
`
`Roxane Labs., Inc.
`Exhibit 1027
`Page 004
`
`

`
`dTOR mutation is associated with G0yG1 accumulation and lack
`of animal viability that can be rescued by overexpression of dS6K
`(32). Such data suggest that inhibition of S6K is an important
`mediator of the antiproliferative effects of mTOR.
`Another regulator of translation and cell growth, 4E-BP1, is
`controlled by the PI3KyAKT and mTOR pathways (24, 25, 43,
`44). In its unphosphorylated state, 4E-BP1 binds to EIF-4E to
`inhibit the translation of 59-capped messages (45). On stimula-
`tion of cell growth, 4E-BP1 becomes phosphorylated and no
`longer inhibits translation. Inhibitors of mTOR block phosphor-
`ylation of 4E-BP1. Although we have not studied 4E-BP1
`phosphorylation, alterations of its function may be contributing
`to the neoplasias that we see.
`We conclude that the tumor stasis and the reduced prolifer-
`ation that we have observed with the rapamycin analog CCI-779
`is in part caused by the inhibition of the elevated S6K activity
`found in the tumors (Figs. 4 and 5). Our findings suggest that S6K
`and possibly other proteins regulated by mTOR contribute to the
`oncogenic effects of Pten loss.
`Although we see a reduction in tumor proliferation in the
`mouse tumors, rapamycin and CCI-779 are not broadly antipro-
`liferative. Rapamycin is well tolerated when administered in vivo
`and inhibits the growth of only a subset of tumors expressing
`mTOR (46). In a recent report by the Vogt lab, rapamycin was
`found to inhibit the growth of fibroblasts transformed with AKT
`and PI3K but had no effect on cells transformed with v-Jun or
`v-Src (47). This group found that the growth of v-H-Ras and
`v-Myc transformants was stimulated by rapamycin. It also has
`been reported that rapamycin is able to induce apoptosis in
`tumors. We have not seen such apoptosis and presume that this
`may be a reflection of the benign nature of the mouse neoplasias.
`Huang et al. have recently shed light on this paradox (48). They
`found that tumor cells and mouse embryo fibroblasts lacking
`intact p53 or p21 were unable to arrest in G1 in response to
`rapamycin and instead underwent apoptosis. However, when the
`p53 pathway was reconstituted or intact, cells arrested in G1 and
`did not die. These data suggest that rapamycin analogs may be
`more potent in the clinical setting in which the PTEN and p53
`pathways are altered.
`We have found that disease progression caused by Pten
`mutation can be delayed by inhibiting mTOR and biochemical
`targets downstream of mTOR such as S6K. This finding suggests
`that enzymes other than AKT are excellent targets for the
`treatment of PTEN2/2 tumors. With respect to human endome-
`trial cancers, which lack PTEN in more than 60% of cases,
`inhibition of mTOR may prove to be a useful agent for patients
`with disease that is refractory to standard treatments. Moreover,
`rapamycin and its analog CCI-779 are well tolerated in people,
`suggesting that there may be a usable therapeutic dose with
`limited systemic toxicity (19). In the future, it will be interesting
`to determine in Pten1/2 mice whether the inducible disruption
`of S6K1, mTOR, or4E-BP1 or a combination of these will have
`antitumor effects that are similar to CCI-779.
`
`We thank Giorgio Cattoretti for his assistance with immunohistochem-
`ical staining and generous sharing of reagents. R.T.L. was supported by
`the Peter Jay Sharp Foundation, the Don Shula Foundation, and the
`American Society of Clinical Oncology. This work was supported by
`National Cancer Institute Grant CA 75553.
`
`Long-term CCI-779 treatment prevents tumor growth and prolifer-
`Fig. 5.
`ation in Pten1/2 without affecting Akt activity. (A) Size of neoplastic lesions in
`mock, untreated (none) and CCI-779-treated (CCI) uteri. All mice are Pten1/2
`females and average age of each cohort is indicated. (B) Size of the untreated
`(none) wild-type (wt), untreated Pten1/2, mock-treated Pten1/2, and CCI-779-
`treated (CCI) Pten1/2 adrenal medullas. (C) Proliferation in mock (n)- and drug
`(h)-treated uteri. BrdUrd-positive cells were counted per total number of
`nuclei in CAH. (D) Proliferation in mock-treated Pten1/2 (n) and CCI-779-
`treated Pten1/2 (h) adrenal medullas. (E and F) Phosoho-473 Akt levels in the
`mock (E)- and drug (F)-treated uteri. (Magnification, 3400).
`
`immunohistochemistry in either treated or untreated lesions
`(40, 41).
`
`Discussion
`It is likely that the loss of Pten found in the tumors of PTEN1/2
`mice leads to increased levels of PtdIns(3,4,5)P3, which in turn
`is able to activate AKT, 3-phosphoinositide-dependent kinase 1,
`S6K, mTOR, and many other proteins. In combination, these
`activated proteins probably contribute to the transformation and
`increased tumor proliferation that was observed in a variety of
`organs (Figs. 1 and 2). Of these activated proteins, S6K is likely
`to play a major role in the progression of the cell cycle into the
`S phase. Microinjection of anti-S6K antibodies into quiescent rat
`embryo fibroblasts prevents the mitogenic effect of serum (32,
`33). In T cells, which are unable to proliferate in the presence of
`rapamycin, a rapamycin-resistant allele of S6K is sufficient to
`rescue the activation of an E2F reporter (42). S6K12/2 mouse
`embryonic stem cells have an elevated proportion of cells in
`G0yG1 and slower proliferation relative to wild type (10). Finally,
`
`1. Ali, I. U., Schriml, L. M. & Dean, M. (1999) J. Natl. Cancer Inst. 91, 1922–1932.
`2. Cantley, L. C. & Neel, B. G. (1999) Proc. Natl. Acad. Sci. USA 96, 4240–4245.
`3. Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C.,
`Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P. & Mak, T. W. (1998)
`Cell 95, 29–39.
`4. Sun, H., Lesche, R., Li, D. M., Liliental, J., Zhang, H., Gao, J., Gavrilova,
`N., Mueller, B., Liu, X. & Wu, H. (1999) Proc. Natl. Acad. S

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket